Related Experiment Video
Updated: Apr 7, 2026

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation
Guido A Gualdoni1, Tilman Lingscheid2, Klaus G Schmetterer3
1Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Abstract:
Deregulation of inflammasome activation was recently identified to be involved in the pathogenesis of various inflammatory diseases. Although macrolide antibiotics display well described immunomodulatory properties, presumably involved in their clinical effects, their impact on inflammasome activation has not been investigated. We compared the influence of macrolides on cytokine induction in human monocytes. The role of intracellular azithromycin-accumulation was examined by interference with Ca(++)-dependent uptake. We have also analysed the signalling cascades involved in inflammasome activation, and substantiated the findings in a murine sepsis model. Azithromycin, but not clarithromycin or roxithromycin, specifically inhibited IL-1α and IL-1β secretion upon LPS stimulation. Interference with Ca(++)-dependent uptake abolished the cytokine-modulatory effect, suggesting a role of intracellular azithromycin accumulation in the modulatory role of this macrolide. Azithromycin's inhibiting effects were observed upon LPS, but not upon flagellin, stimulation. Consistent with this observation, we found impaired induction of the LPS-sensing caspase-4 whereas NF-κB signalling was unaffected. Furthermore, azithromycin specifically affected IL-1β levels in a murine endotoxin sepsis model. We provide the first evidence of a differential impact of macrolides on the inflammasome/IL-1β axis, which may be of relevance in inflammasome-driven diseases such as chronic obstructive pulmonary disease or asthma.
Insights
Azithromycin, but not other macrolides, inhibits inflammasome activation by accumulating intracellularly. This finding is relevant for treating inflammatory diseases like COPD and asthma.
Area of Science:
- Immunology
- Pharmacology
Background:
- Inflammasome activation deregulation is implicated in inflammatory diseases.
- Macrolide antibiotics have known immunomodulatory effects, but their impact on inflammasomes is unclear.
Purpose of the Study:
- To investigate the differential effects of macrolides on inflammasome activation.
- To explore the mechanisms underlying azithromycin's immunomodulatory properties.
Main Methods:
- Comparing macrolide influence on cytokine induction in human monocytes.
- Examining intracellular azithromycin accumulation via Ca(++)-dependent uptake.
- Analyzing inflammasome signaling cascades and validating findings in a murine sepsis model.
Main Results:
- Azithromycin, unlike clarithromycin and roxithromycin, inhibited IL-1α and IL-1β secretion induced by LPS.
- Inhibition of cytokine release by azithromycin required Ca(++)-dependent intracellular accumulation.
- Azithromycin specifically inhibited LPS-induced caspase-4 activation, not flagellin-induced activation, and reduced IL-1β in a murine sepsis model.
Conclusions:
- Macrolides exhibit differential effects on the inflammasome/IL-1β axis.
- Intracellular azithromycin accumulation is key to its inflammasome-modulatory effects.
- Findings suggest potential therapeutic applications for azithromycin in inflammasome-driven diseases.
Related Concept Videos
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Inhibitors of Viral Protein Synthesis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inhibitors of Bacterial Protein Synthesis
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

